Bedside Snapshot

Use It For: Osteoarthritis and rheumatoid arthritis; juvenile arthritis (age ≥2 yr); short-course musculoskeletal pain (off-label); moderate-to-severe acute pain in hospitalized adults (IV)
Adult Dose: Arthritis: 7.5 mg PO once daily, may increase to 15 mg (max 15 mg/day, any oral form)
Hemodialysis: max 7.5 mg/day
IV (Qamzova): 30 mg IV bolus over 15 seconds once daily (max 30 mg/day)
Pediatric Dose: Juvenile arthritis, age ≥2 yr: 0.125 mg/kg PO once daily as suspension (max 7.5 mg); tablets only if ≥60 kg. Acute pain or IV use: not established in children
Onset / Duration: PO: slow; plasma peak 4–5 hr / 24 hr, steady state by day 5. IV: meaningful relief at a median 2–3 hr / 24 hr
Do Not Give / Hold If: Asthma, urticaria or allergy after aspirin or an NSAID; CABG setting; active GI bleeding; severe renal impairment or uncorrected volume depletion; pregnancy ≥30 wk; already on another NSAID
Watch For: GI bleeding, often painless (melena, falling hemoglobin); AKI and hyperkalemia (creatinine, K⁺, urine output); MI or stroke; fluid retention (weight, edema, BP)
Reversal / Rescue: No antidote: stop and support. GI bleed: resuscitate, IV proton-pump inhibitor; anaphylaxis: IM epinephrine. Overdose: cholestyramine speeds clearance; dialysis does not remove it
Must Remember: Oral max is 15 mg/day, and never stack NSAIDs. Ask about over-the-counter ibuprofen or naproxen before giving any NSAID; the 15–20 hr half-life means effects outlast the dose.

Indications

ED / ICU / Transport

Moderate-to-severe acute pain in adults (IV meloxicam, Qamzova): a once-daily hospital analgesic. Use it alone or with non-NSAID analgesics. It is not the choice when rapid relief is needed, because onset is delayed.
Postsurgical analgesia for up to 72 hr (bupivacaine/meloxicam, Zynrelef): a single dose, instilled by the surgical team into the surgical site after soft-tissue and selected orthopedic procedures
Acute musculoskeletal pain, short course: an oral NSAID option, once fracture, infection and other serious causes are excluded (off-label). Topical NSAIDs come first for non-low-back musculoskeletal injuries

Other Uses

Osteoarthritis: relief of signs and symptoms (FDA-labeled). The ACR 2026 summary (full manuscript pending) strongly recommends topical NSAIDs for knee and hand osteoarthritis, and oral NSAIDs for knee, hip and hand osteoarthritis. For knee and hand, topical is conditionally preferred over oral
Rheumatoid arthritis: the FDA label covers relief of signs and symptoms
Juvenile rheumatoid arthritis, pauciarticular or polyarticular course: from age 2 yr as an oral suspension. Tablets are used only at ≥60 kg (FDA-labeled)

Patients usually arrive already taking it, so expect to find it on the med list. Treat it as an active NSAID. Keep it in mind when you assess GI bleeding, acute kidney injury, hyperkalemia or heart failure, and when someone asks for another NSAID such as ketorolac.

Dosing & Administration

Doses vary by protocol; follow local protocols and medical direction.

Available Forms

Tablets: 7.5 mg and 15 mg (generic). The usual form.
Oral suspension: 7.5 mg/5 mL (1.5 mg/mL). The choice for weight-based pediatric doses.
Injection (Qamzova): 30 mg/mL in 1 mL (30 mg) single-dose vial, IV only. Hospital use.
Bupivacaine/meloxicam (Zynrelef): single-dose kits with 1.8–12 mg meloxicam. The surgical team instills it into the surgical site. Instillation only, a route outside the IV/PO list above. Never epidural, intrathecal, intravascular or intra-articular. No other local anesthetic for 96 hr afterward.

Adult Dosing

Indication	Dose & Route	Repeat / Max	Notes
Osteoarthritis or rheumatoid arthritis	7.5 mg PO once daily; may increase to 15 mg PO once daily	Max 15 mg/day, whatever the oral formulation	Lowest effective dose for the shortest time. Doses of 22.5 mg/day and higher raise the risk of serious GI events.
Acute musculoskeletal pain, short course (off-label)	7.5–15 mg PO once daily	Max 15 mg/day; shortest duration possible	Topical NSAID first-line for non-low-back injury. Slow onset: not a choice for rapid relief.
Hemodialysis	7.5 mg PO once daily	Max 7.5 mg/day; no extra dose after dialysis	Not dialyzable. Severe renal impairment without dialysis: not recommended.
Moderate-to-severe acute pain, hospital (Qamzova)	30 mg IV bolus over 15 seconds once daily	Max 30 mg/day; shortest duration possible	Hydrate first. Median 2–3 hr to meaningful relief: add a rapid-onset non-NSAID analgesic. Not recommended in moderate or severe renal impairment.

Pediatric Dosing

Indication	Dose (per kg) & Route	Max Single / Max Total	Notes
Juvenile rheumatoid arthritis, age ≥2 yr	0.125 mg/kg PO once daily, as the 7.5 mg/5 mL suspension	Max 7.5 mg/day	No added benefit above 0.125 mg/kg. Label examples: 12 kg = 1 mL (1.5 mg); 24 kg = 2 mL (3 mg); 48 kg = 4 mL (6 mg).
Juvenile rheumatoid arthritis, weight ≥60 kg	7.5 mg PO once daily (tablet or 5 mL suspension)	Max 7.5 mg/day	Do not use tablets in children under 60 kg.
Acute pain; IV meloxicam; age <2 yr	Not established in children	Not routinely used (consult)	Use ibuprofen or acetaminophen per protocol.

Check weight and dose against pediatric weight-based dosing.

Preparation & Administration

Food: take it with or without food. Antacids do not change absorption.
Suspension: shake gently. The suspension label allows 7.5 mg/5 mL in place of a 7.5 mg tablet. Both labels say each product is not interchangeable with other oral meloxicam formulations, even at the same mg strength (e.g. Vivlodex capsules). Check with pharmacy before switching products.
IV push (Qamzova): 15-second bolus from the 1 mL vial. The solution is clear greenish-yellow. Discard it if discolored or particulate.
Before any dose: correct dehydration or hypovolemia. Ask about over-the-counter ibuprofen, naproxen or aspirin.

Dosing Notes:

Whatever the formulation, the oral ceiling is 15 mg/day.
Over-the-counter products count. One NSAID at a time.
For renal and hepatic adjustments, look at Special Populations.

Contraindications & Precautions

Contraindications

Known hypersensitivity to meloxicam, including anaphylaxis or a serious skin reaction
Asthma, urticaria or an allergic-type reaction after aspirin or any NSAID; prior serious skin reaction to an NSAID
The setting of coronary artery bypass graft (CABG) surgery
IV meloxicam only: moderate or severe renal insufficiency with risk of renal failure from volume depletion

Precautions

Active GI bleeding, prior ulcer or GI bleed: avoid. After a prior ulcer or bleed, GI bleeding risk climbs more than 10-fold.
Recent myocardial infarction (MI) or severe heart failure: avoid unless the benefit clearly outweighs the risk.
Kidney disease, dehydration, heart failure, cirrhosis: high acute kidney injury (AKI) risk. Correct volume first. Severe renal impairment: not recommended. Avoid starting meloxicam in hemodynamically unstable or critically ill patients with fluctuating renal function. Its 15–20 hr half-life keeps any renal or GI harm going.
Asthma without known aspirin sensitivity: monitor for bronchospasm or worsening asthma.
Anticoagulants, coagulopathy, advanced liver disease: higher bleeding risk.
Possible infection or sepsis: meloxicam dials down inflammation and possibly fever. A patient on daily meloxicam may not mount a fever despite infection.

Hold / Reassess If

Melena, hematemesis or a falling hemoglobin: stop until a serious GI event is ruled out
Rising creatinine or potassium, or falling urine output: stop and assess volume status
Any rash or other sign of hypersensitivity: stop at the first sign
Jaundice, right upper quadrant pain, liver tests that persist or worsen, or rash with fever and eosinophilia: stop and evaluate

FDA Boxed Warning: NSAIDs raise the risk of serious and sometimes fatal MI and stroke. That risk may start early in treatment. Meloxicam is contraindicated in the setting of CABG surgery. NSAIDs also cause serious, sometimes fatal, GI bleeding, ulceration and perforation. Often there is no warning. Older adults and anyone with a prior ulcer or GI bleed are at greatest risk.

Adverse Effects & Toxicity

Common

GI events are the most frequent. About 12–27% of meloxicam-treated patients reported them across the label's arthritis trials. Placebo patients reported them too: 17% in the 12-week osteoarthritis trial:

GI: dyspepsia (about 4–10%), diarrhea (2–8%), nausea (2–7%), abdominal pain (2–5%)
CNS: headache (2–8%, similar to placebo), dizziness (1–4%)
Cardiovascular: edema (up to 5%), new or worse hypertension
Other: rash (up to 3%); anemia (about 3–4% in 6-month trials)
Children: abdominal pain, vomiting, diarrhea, headache and fever all show up more often than in adults

Serious / Life-Threatening

Effect	Recognition	Management
GI bleeding, ulcer, perforation	Melena, hematemesis, falling hemoglobin; only 1 in 5 has warning symptoms. About 1% at 3–6 months, 2–4% at 1 yr	Stop; resuscitate; GI bleed pathway (IV pantoprazole, endoscopy)
MI, stroke	Chest pain, ST changes, focal deficit; risk can start in the first weeks	Stop; ACS or stroke pathway
AKI, hyperkalemia	Low urine output, rising creatinine and K⁺	Stop; restore volume; treat hyperkalemia per protocol
Heart failure, edema, hypertension	Weight gain, edema, dyspnea, rising BP	Stop or reassess; treat fluid overload
Anaphylaxis, bronchospasm	Wheeze, urticaria, hypotension; can occur on first exposure	Stop; IM epinephrine and anaphylaxis protocol
Stevens-Johnson syndrome/toxic epidermal necrolysis, fixed drug eruption, drug reaction with eosinophilia (DRESS)	Rash, blistering, mucosal lesions; fixed drug eruption can become a life-threatening generalized bullous form; fever, facial edema, eosinophilia	Stop at the first rash; never rechallenge
Hepatotoxicity	ALT/AST ≥3 times normal in about 1%; jaundice, right upper quadrant pain	Stop; evaluate liver function

Overdose & Toxicity Management

Signs: lethargy, drowsiness, nausea, vomiting, epigastric pain; GI bleeding. Rare: hypertension, AKI, respiratory depression, coma.
Management: supportive care. There is no antidote. Consider activated charcoal (adults 60–100 g; children 1–2 g/kg) if symptomatic within 4 hr of ingestion or after a large overdose (5–10 times the recommended dose), with a protected airway. Call Poison Control (1-800-222-1222).
Enhanced elimination: cholestyramine 4 g PO three times daily speeds meloxicam clearance. It interrupts enterohepatic recycling. Hemodialysis, hemoperfusion, forced diuresis and urine alkalinization are unlikely to help. The drug is 99.4% protein bound.

Monitoring

Parameter	When / How Often	Target / Act If
Clinical: GI bleeding signs	Every assessment; ask about stool color and dyspepsia	Melena, hematemesis, new abdominal pain: stop, check hemoglobin, notify the provider
Clinical: BP, weight, edema	At the start and throughout therapy; closely in heart failure	New hypertension, weight gain or worsening heart failure: reassess or stop
Laboratory: creatinine, BUN	Baseline and periodically if older, or with kidney disease, heart failure, cirrhosis or ACE inhibitor/ARB/diuretic use	Rising creatinine: stop, assess volume status
Laboratory: potassium	With renal labs in at-risk patients	Rising K⁺: stop, treat hyperkalemia per protocol
Laboratory: CBC, chemistry profile	Periodically on long-term therapy (bleeding, liver and kidney injury can be silent)	Falling hemoglobin: evaluate for GI blood loss
Laboratory: ALT, AST	Long-term therapy or liver symptoms	Signs of liver disease, systemic features (eosinophilia, rash), or ALT/AST abnormalities that persist or worsen: stop, evaluate. Mild rises (under 3 times normal) occur in up to 15%
Drug levels: INR, lithium	When meloxicam starts or stops in a patient on warfarin or lithium	INR or lithium level rising: adjust and monitor for bleeding or lithium toxicity
Pregnancy: amniotic fluid	Use beyond 48 hr at 20–30 weeks	Oligohydramnios on ultrasound: stop meloxicam

Interactions & Compatibility

Clinically Significant Interactions

Drug / Class	Effect	What To Do
Anticoagulants and antiplatelets (warfarin, heparin, clopidogrel)	Synergistic bleeding risk; INR may change with warfarin	Avoid if possible; otherwise monitor closely for bleeding and check INR
Aspirin, low or analgesic dose	More GI bleeding with no added analgesia; meloxicam does not replace cardioprotective aspirin	Combination not generally recommended; if both are needed, monitor closely for GI bleeding
Other NSAIDs and salicylates (ketorolac, ibuprofen, naproxen, diflunisal)	More GI toxicity with little or no added efficacy	Do not combine; ketorolac labeling contraindicates use with other NSAIDs
Selective serotonin reuptake inhibitors (SSRIs), SNRIs, corticosteroids	Higher GI bleeding risk	Monitor for bleeding; prefer another analgesic in high-risk patients
ACE inhibitors, ARBs, beta-blockers, diuretics (furosemide, thiazides)	Blunted BP and diuretic response; AKI in older, volume-depleted or renally impaired patients	Hydrate; check renal function at the start and periodically; monitor BP
CYP2C9 inhibitors (amiodarone, fluconazole)	Higher meloxicam levels from reduced clearance	Consider a lower dose and monitor for adverse effects (IV label)
Lithium	Lithium levels about 21% higher with meloxicam 15 mg daily	Monitor levels and for lithium toxicity
Methotrexate, pemetrexed, cyclosporine	Methotrexate or pemetrexed toxicity (myelosuppression, renal injury); more cyclosporine nephrotoxicity	Monitor for toxicity and renal function. Pemetrexed with CrCl 45–79 mL/min: hold meloxicam for at least 5 days before, the day of, and 2 days after each dose; CrCl <45 mL/min: combination not recommended

IV Compatibility

Qamzova: Given as a 15-second IV bolus from the single-dose vial. The label gives no dilution or Y-site compatibility data.
Verify with an institutional compatibility resource.

Special Populations

Pediatrics: Labeled only for juvenile rheumatoid arthritis: from age 2 yr as a suspension, or at ≥60 kg as tablets. See the Pediatric Dosing table. Not studied under 2 yr. IV and acute-pain use are not established.
Pregnancy: Starting around 20 weeks, NSAIDs can cause fetal renal dysfunction, oligohydramnios and neonatal renal impairment. Needed at 20–30 weeks? Use the lowest dose for the shortest time, and consider ultrasound if use runs past 48 hr. Avoid from about 30 weeks, when the ductus arteriosus can close early. Earlier-pregnancy data are inconclusive, so prefer a non-NSAID analgesic. NSAIDs may also cause reversible female infertility.
Lactation: There are no human data on milk transfer or infant effects. In rats, milk levels exceeded plasma levels. Weigh the need against possible infant effects, or choose an alternative.
Older Adults: AGS Beers Criteria 2023 says avoid chronic use unless alternatives fail and the patient can take a gastroprotective agent. Avoid short-term scheduled use with oral or parenteral corticosteroids, anticoagulants or antiplatelet agents unless alternatives are not effective and the patient can take a gastroprotective agent (PPI or misoprostol). Start at 7.5 mg. Most fatal GI events happen in older or debilitated patients.
Renal Impairment: Mild to moderate: no labeled dose change, but monitor renal function. Severe: not recommended. It has not been studied. AGS Beers says avoid NSAIDs at CrCl <30 mL/min. Hemodialysis: max 7.5 mg/day. Not dialyzable. No supplemental dose. IV meloxicam is not recommended in moderate or severe impairment.
Hepatic Impairment: Mild to moderate (Child-Pugh A–B): no dose change. Severe: not adequately studied, so use with caution. Advanced liver disease or coagulopathy pushes GI bleeding risk up.
Obesity / Dosing Weight: Adult doses are fixed. They do not change with weight. Pediatric doses use body weight, with a 7.5 mg cap.
Heart Failure: AGS Beers says avoid it in symptomatic heart failure and use caution if asymptomatic. NSAIDs roughly double heart failure hospitalizations.
CYP2C9 Poor Metabolizers: Exposure is substantially higher in under 5% of people. The IV label advises considering a dose reduction when poor metabolism is known or suspected, from genotype or from prior experience with CYP2C9 substrates such as warfarin or phenytoin.

Clinical Pearls

Count every NSAID: Patients often take over-the-counter ibuprofen or naproxen along with prescribed meloxicam. Ask before you give ketorolac or any NSAID. Stacking adds GI and renal toxicity for little extra relief.

Volume before NSAID: Dehydration, heart failure, cirrhosis, or an ACE inhibitor or ARB plus a diuretic. In each, the kidneys lean on prostaglandins. Take that support away with an NSAID and you can trigger AKI and hyperkalemia.

COX-2 preference is not a safety pass: At low doses, meloxicam favors COX-2. It still inhibits COX-1 and carries the same boxed warnings as other NSAIDs. Serious GI events rise at 22.5 mg/day and higher. Pooled observational data put its GI-bleeding odds at roughly 7 times those of non-users, far above celecoxib.

Home medication in the ED: Melena, unexplained anemia, AKI, hyperkalemia or new edema? Ask about meloxicam. Its 15–20 hr half-life and enterohepatic recycling mean the effect outlasts the last dose.

Exam discriminator: meloxicam vs ketorolac: Meloxicam is a once-daily oral arthritis NSAID with a slow onset. Its peak is at 4–5 hr. Ketorolac IV or IM works in about 30 min for acute pain, and its use is limited to 5 days. Neither is controlled. Both share the NSAID GI, renal and bleeding risks.

Pharmacology

Mechanism of Action

It inhibits COX-1 and COX-2, with relative COX-2 preference at low doses. Less prostaglandin synthesis gives analgesic, anti-inflammatory and antipyretic effects.
Gastric prostaglandin loss means weaker mucosal protection. That opens the door to ulceration and bleeding.
Renal prostaglandin loss cuts renal blood flow when perfusion depends on prostaglandins. The result: AKI, sodium retention, hyperkalemia.
No opioid activity. No sedation or respiratory depression at therapeutic doses.

Pharmacokinetics

Route	Onset	Peak	Duration
PO	Slow (prolonged absorption)	4–5 hr (plasma); second peak at 12–14 hr	24 hr (once daily); steady state by day 5
IV	Median 2–3 hr to meaningful pain relief	About 6 min (plasma)	24 hr (once daily); some patients need rescue analgesia

Half-life: 15–20 hr oral; about 21 hr IV. Dose does not change it.
Bioavailability: 89% oral. Food does not change the extent of absorption.
Metabolism: extensive hepatic oxidation, mainly by CYP2C9 with a minor CYP3A4 contribution, plus peroxidase pathways. All four metabolites are inactive.
Elimination: metabolites leave in urine and feces in equal amounts. Only traces leave unchanged. Biliary recycling explains the second peak and the effect of cholestyramine.
Protein binding / Vd: 99.4% bound, mainly to albumin. Vd about 10 L. Not dialyzable.

Names & Classification

Generic Name: Meloxicam
Brand Names: Mobic (original brand); Qamzova (IV injection); Zynrelef (bupivacaine and meloxicam, surgical instillation); Vivlodex (capsules, not interchangeable)
Pharmacologic Class: Nonsteroidal anti-inflammatory drug (NSAID), oxicam group; COX-1 and COX-2 inhibitor with relative COX-2 preference
Therapeutic Class: Non-opioid analgesic; anti-inflammatory (antiarthritic)
Controlled Substance: Not controlled
ISMP High-Alert: No
Look-Alike / Sound-Alike: Check the institution's confused-drug-names list. Formulation trap: tablets, Vivlodex capsules and IV meloxicam are not interchangeable mg-for-mg.

References

Carlsbad Technology, Inc. (2024). Meloxicam tablets, USP [prescribing information] (revised December 2024). DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20871c7f-1e36-49ef-8e2b-70112430ca1e
Avondale Pharmaceuticals, LLC. (2024). Meloxicam oral suspension, 7.5 mg/5 mL [prescribing information] (revised November 2024). DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ddf5a4d-8e84-419d-8e3a-c91b85501885
Nanjing Delova Biotech Co., Ltd. (2025). QAMZOVA (meloxicam) injection, for intravenous use [prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=385fd779-1be1-49ae-8213-750b96ecc997
Heron Therapeutics, Inc. (2026). ZYNRELEF (bupivacaine and meloxicam) extended-release solution, for soft tissue or periarticular instillation [prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dab484a7-9353-43ba-9e74-7fab910c712b
Qaseem, A., McLean, R. M., O'Gurek, D., Batur, P., Lin, K., & Kansagara, D. L. (2020). Nonpharmacologic and pharmacologic management of acute pain from non-low back, musculoskeletal injuries in adults: A clinical guideline from the American College of Physicians and American Academy of Family Physicians. Annals of Internal Medicine, 173(9), 739–748. https://doi.org/10.7326/M19-3602
American College of Rheumatology. (2026). 2026 update of the American College of Rheumatology recommendations for the management of osteoarthritis of the knee, hip, and hand [guideline summary] (posted September 14, 2026). https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltb3d12c34020da842/oa-guideline-summary-2026.pdf
2023 American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052–2081. https://doi.org/10.1111/jgs.18372
Tawfik, A. G., Gomez-Lumbreras, A., Del Fiol, G., Kawamoto, K., Trinkley, K. E., Reese, T., Jones, A., & Malone, D. C. (2026). Nonsteroidal anti-inflammatory drugs and risk of gastrointestinal bleeding: A systematic review and meta-analysis. Clinical Pharmacology & Therapeutics, 119(1), 46–62. https://doi.org/10.1002/cpt.70054

Last updated October 2026 Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer

For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.

AI Assistance Notice

AI was used to assist in organizing, paraphrasing, and formatting this information.